Form 4: KalVista CEO Sells Shares to Cover Tax Obligations

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported the acquisition of shares from RSU settlements and a subsequent sale to cover tax withholding obligations.

Summary

• Benjamin L. Palleiko, CEO and Director of KalVista Pharmaceuticals, Inc., reported transactions involving the company's common stock.
• On November 17, 2025, Palleiko acquired 9,364 shares of common stock through the settlement of Restricted Stock Units (RSUs).
• Following this, on November 18, 2025, Palleiko sold 4,466 shares of common stock at a weighted average price of $14.4794 per share.
• The sale was explicitly stated to cover tax withholding obligations related to the vesting and settlement of RSUs and was not a discretionary transaction.
• The shares were sold in multiple transactions within a price range of $14.16 to $14.4835 per share.
• After these transactions, Palleiko beneficially owns 403,879 shares of KalVista Pharmaceuticals, Inc. common stock directly.
• Two tranches of Restricted Stock Units (RSUs) were settled on November 17, 2025, converting 2,419 and 6,945 units respectively into common stock.
• The RSUs represent a contingent right to receive one share of common stock upon settlement for no consideration.
• The vesting schedules for the RSUs were 1/16th of the total shares vesting quarterly and 1/12th of the total shares vesting quarterly, subject to continued service.

Sentiment

Score: 5

Explanation: The transaction involves the acquisition of shares through RSU settlement, which increases the insider's stake, immediately followed by a 'sell to cover' transaction for tax withholding. This is a routine, non-discretionary event for equity compensation and does not indicate a change in sentiment regarding the company's future.

Positives

• The acquisition of 9,364 shares of common stock through RSU settlements increases the CEO's direct equity stake in the company before the tax-related sale.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned and non-discretionary nature for the sale.

Negatives

• The sale of 4,466 shares of common stock, even for tax purposes, reduces the CEO's direct beneficial ownership by that amount.

Future Outlook

NA

Industry Context

This Form 4 filing details a routine insider transaction for a biotechnology company executive, specifically related to equity compensation and tax obligations. Such 'sell to cover' transactions are common across industries, particularly in sectors where executive compensation frequently includes Restricted Stock Units or stock options, and do not typically reflect a change in the executive's view of the company's prospects.

Stakeholder Impact

• Shareholders: A minor reduction in the CEO's direct beneficial ownership due to the tax-related sale, which is a common occurrence with equity compensation. The transaction is pre-planned and non-discretionary, mitigating concerns about insider selling.

Key Dates

Keywords

KalVista Pharmaceuticals, KALV, Benjamin L. Palleiko, SEC Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU, CEO, Director, Equity Compensation, Tax Withholding, Rule 10b5-1